- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
HitGen Inc (688222)
The HitGen share price today is 35.87, view SS 688222 stock exchange data. Track the latest HitGen share price with real-time updates on 688222 stock performance including market cap, day range, 52-week range and dividend yield. Access 688222 charts, earnings dates and analyst estimates to support your investment decisions.
Shanghai
Currency in CNY
35.87
+2.42(+7.23%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
32.60
36.90
52 wk Range
17.18
42.98
688222 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
32.6036.90
52 wk Range
17.1842.98
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.39%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.39%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
688222 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
31.60
Downside
-11.90%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Significant return over the last week
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 31.60
(-11.90% Downside)
Earnings
Latest Release
29-04-2026
EPS / Forecast
-- / --
Revenue / Forecast
161M / --
Compare 688222 to Peers and Sector
Metrics to compare | 688222 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship688222PeersSector | |
|---|---|---|---|---|
P/E Ratio | 117.1x | 33.2x | −0.4x | |
PEG Ratio | 1.59 | 0.31 | 0.00 | |
Price/Book | 9.3x | 3.2x | 2.6x | |
Price / LTM Sales | 24.8x | 4.3x | 3.0x | |
Upside (Analyst Target) | −11.9% | 25.8% | 51.5% | |
Fair Value Upside | Unlock | 24.5% | 8.8% | Unlock |
HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology. The company’s product pipeline also includes HG146, a selective HDAC inhibitor for multiple myeloma and solid tumor; HG030, a second generation NTRK/ROS1 inhibitor tablet for solid tumor; HG153 a Menin-MLL tablet; HG248; HG 381, an immune-oncology agonist for cancer, as well as HGP0508, a small molecule for anti-inflammatory therapeutics for inflammation; and HGP1069, a ROCK2 inhibitor eye drop. In addition, it offers target validation, hit identification, hit-to-lead optimization, lead optimization, preclinical studies and IND, clinical development, and integrated drug discovery services. Further, the company focuses on oncology and immuno-oncology, inflammatory and autoimmune diseases, ophthalmology, infectious, metabolic, and cardiovascular diseases. The company was incorporated in 2012 and is based in Chengdu, China.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the HitGen (688222) Share Price Today?
The HitGen share price today is 35.87.
What is the current HitGen (688222) share price and day range?
As of 11-07-2026, the HitGen share price is 35.87, with a previous close of 33.45. The share price has ranged from 32.60 to 36.90 today, while the 52-week range spans from 17.18 to 42.98.
What Is the HitGen Market Cap?
As of today, HitGen market cap is 14.37B.
Does HitGen Pay Dividends? What's The Current Dividend Yield?
The HitGen dividend yield is 0.39%.
What Is the HitGen (688222) Share Price Target?
The average 12-month share price target for HitGen is 31.60, with a high estimate of 31.6 and a low estimate of 31.6. 4 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and -11.90% Downside potential.
What Is HitGen's Earnings Per Share (TTM)?
The HitGen EPS (TTM) is 0.30.
When Is the Next HitGen Earnings Date?
HitGen will release its next earnings report on 27-08-2026.
From a Technical Analysis Perspective, Is 688222 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does HitGen Trade On?
HitGen is listed and trades on the Shanghai Stock Exchange.
What Is the Stock Symbol for HitGen?
The stock symbol for HitGen is "688222."
How Many Times Has HitGen Stock Split?
HitGen has split 0 times.
How Many Employees Does HitGen Have?
HitGen has 546 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.